https://pharminent.com/week-in-review/week-in-review-intelligence-brief-july-11-2026/ 2026-07-11T21:13:39Z Pharminent en Week in Review • INTELLIGENCE BRIEF • July 11, 2026 2026-07-11T21:13:37Z Blog https://pharminent.com/orca-bios-tregzi-wins-fda-approval-for-allogeneic-stem-cell-transplant/ 2026-07-11T21:43:56Z Pharminent en Roche Scraps Two Ionis-Partnered Huntington's Studies After Tominersen Failure 2026-07-10T21:26:01Z Blog https://pharminent.com/hengrui-kailera-oral-glp-1-phase-3-data-lands-from-china/ 2026-07-10T21:25:57Z Pharminent en Hengrui-Kailera Oral GLP-1 Phase 3 Data Lands From China 2026-07-10T21:25:57Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-july-10-2026/ 2026-07-10T21:17:17Z Pharminent en GLP-1 Competitive Market Digest • Weekly • July 10, 2026 2026-07-10T21:17:12Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-10-2026/ 2026-07-10T16:37:41Z Pharminent en Strategic News Watch • July 10, 2026 2026-07-10T16:37:39Z Blog https://pharminent.com/aaic-2026-tau-targeted-alzheimers-treatments-heat-up-while-amyloid-therapies-persist/ 2026-07-10T20:43:52Z Pharminent en AAIC 2026: Tau-targeted Alzheimer's treatments heat up while amyloid therapies persist 2026-07-10T14:31:07Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-9-2026/ 2026-07-10T13:19:37Z Pharminent en Rare Disease & Gene Therapy Digest • July 9, 2026 2026-07-10T13:19:35Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-july-3-2026/ 2026-07-10T13:17:13Z Pharminent en Oncology Intelligence Digest • July 3, 2026 2026-07-10T13:17:11Z Blog https://pharminent.com/teva-and-polpharma-biologics-sign-global-deal-for-ocrelizumab-biosimilar-2/ 2026-07-10T20:41:53Z Pharminent en Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar 2026-07-10T09:31:18Z Blog